Literature DB >> 16724209

Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas.

Maky A Hafidh1, Peter D Lacy, Joe P Hughes, George Duffy, Conrad V Timon.   

Abstract

The addition of whole body positron emission tomography (PET) to the investigation of patients with newly diagnosed head and neck squamous cell carcinoma (HNSCC) was assessed over a 6-month period. Staging investigations included laryngoscopy, oesophagoscopy, CXR, CT and MRI. In addition, all patients had an extended-field (whole body) FDG-PET scan and were restaged. Standardised Uptake Values (SUV) were used to measure FDG uptake. SUV levels above 5 were considered indicative of the presence of tumour, values below 3 indicative of benign aetiology and values equal to and between 3 and 5 were considered equivocal. Forty-eight consecutive patients with biopsy proven HNSCC were included for study. Three patients presenting with neck disease had unknown primary tumours. Of the remaining 45 patients, CT scan correctly identified 40 of the primary tumours (89%). MRI and PET both identified 41 primary tumours (91%). Thirty-two patients underwent neck dissection. Of these patients 12 had pathologically N0 necks and 20 had positive nodal disease. CT scan and MRI each correctly staged pN0 necks in 10 of 12 patients (83%) whereas PET alone had a lower true negative rate of 8 out of 12 patients (67%). PET correctly staged the N+ necks in 14/20 patients (70%) versus 12/20 (60%) for MRI, and 8/20 (40%) for CT alone. All four patients who were judged to have distant metastases by PET had these metastases deemed negative by other investigation. None of the three imaging modalities was able to identify the tumour site in the three patients with unknown primaries. In conclusion, although PET has got a higher sensitivity in detecting nodal disease, it has only slightly improved the classification of N+ necks. The findings of this study cast doubt on the merit of routine addition of PET to the current investigative protocols for HNSCC patients.

Entities:  

Mesh:

Year:  2006        PMID: 16724209     DOI: 10.1007/s00405-006-0067-1

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  28 in total

1.  Diagnostic tests 3: receiver operating characteristic plots.

Authors:  D G Altman; J M Bland
Journal:  BMJ       Date:  1994-07-16

2.  FDG PET evaluation of head and neck cancer: value of imaging the thorax.

Authors:  J W Keyes; M Y Chen; N E Watson; K M Greven; W F McGuirt; D W Williams
Journal:  Head Neck       Date:  2000-03       Impact factor: 3.147

3.  Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer.

Authors:  Mark K Wax; Larry L Myers; Edward C Gabalski; Syed Husain; Jayakumari M Gona; Hani Nabi
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-06

4.  FDG PET in head and neck cancer.

Authors:  J W Keyes; N E Watson; D W Williams; K M Greven; W F McGuirt
Journal:  AJR Am J Roentgenol       Date:  1997-12       Impact factor: 3.959

5.  Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma.

Authors:  Sandro J Stoeckli; Hans Steinert; Madeleine Pfaltz; Stephan Schmid
Journal:  Head Neck       Date:  2002-04       Impact factor: 3.147

6.  Computed tomography and ultrasonographic evaluation of metastatic cervical lymph nodes with surgicoclinicopathologic correlation.

Authors:  K Sarvanan; J Rajiv Bapuraj; Suresh C Sharma; B D Radotra; N Khandelwal; S Suri
Journal:  J Laryngol Otol       Date:  2002-03       Impact factor: 1.469

7.  Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose.

Authors:  Abdelkarim S Allal; Daniel O Slosman; Tayeb Kebdani; Mohamed Allaoua; Willy Lehmann; Pavel Dulguerov
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-08-01       Impact factor: 7.038

8.  Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.

Authors:  Heiko Schöder; Henry W D Yeung; Mithat Gonen; Dennis Kraus; Steven M Larson
Journal:  Radiology       Date:  2004-02-27       Impact factor: 11.105

9.  Staging of head and neck squamous cell cancer with extended-field FDG-PET.

Authors:  David L Schwartz; Joseph Rajendran; Bevan Yueh; Marc Coltrera; Yoshimi Anzai; Kenneth Krohn; Janet Eary
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-11

10.  Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas.

Authors:  C Laubenbacher; D Saumweber; C Wagner-Manslau; R J Kau; M Herz; N Avril; S Ziegler; C Kruschke; W Arnold; M Schwaiger
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

View more
  11 in total

1.  Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685.

Authors:  Val J Lowe; Fenghai Duan; Rathan M Subramaniam; JoRean D Sicks; Justin Romanoff; Twyla Bartel; Jian Q Michael Yu; Brian Nussenbaum; Jeremy Richmon; Charles D Arnold; David Cognetti; Brendan C Stack
Journal:  J Clin Oncol       Date:  2019-02-15       Impact factor: 44.544

2.  18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes.

Authors:  Rosario Mazzola; Pierpaolo Alongi; Francesco Ricchetti; Alba Fiorentino; Sergio Fersino; Niccolò Giaj-Levra; Matteo Salgarello; Filippo Alongi
Journal:  Radiol Med       Date:  2017-08-28       Impact factor: 3.469

3.  Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis.

Authors:  Jon Cacicedo; Iratxe Fernandez; Olga Del Hoyo; Ainara Dolado; Javier Gómez-Suarez; Eduardo Hortelano; Aintzane Sancho; Jose I Pijoan; Julio Alvarez; Jose M Espinosa; Ayman Gaafar; Pedro Bilbao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-08       Impact factor: 9.236

Review 4.  Use of PET in Head and Neck Cancers.

Authors:  Halil Erdem Özel
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-06-01

Review 5.  The diagnosis and treatment of oral cavity cancer.

Authors:  Klaus-Dietrich Wolff; Markus Follmann; Alexander Nast
Journal:  Dtsch Arztebl Int       Date:  2012-11-30       Impact factor: 5.594

6.  Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI.

Authors:  Benedikt Michael Schaarschmidt; Philipp Heusch; Christian Buchbender; Marcus Ruhlmann; Christoph Bergmann; Verena Ruhlmann; Marc Schlamann; Gerald Antoch; Michael Forsting; Axel Wetter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-06       Impact factor: 9.236

Review 7.  Computed tomography versus magnetic resonance imaging for diagnosing cervical lymph node metastasis of head and neck cancer: a systematic review and meta-analysis.

Authors:  J Sun; B Li; C J Li; Y Li; F Su; Q H Gao; F L Wu; T Yu; L Wu; L J Li
Journal:  Onco Targets Ther       Date:  2015-06-08       Impact factor: 4.147

8.  Impact of 3T multiparametric MRI and FDG-PET-CT in the evaluation of occult primary cancer with cervical node metastasis.

Authors:  Mária Gődény; Zsolt Lengyel; Gábor Polony; Zoltán Takácsi Nagy; Gergely Léránt; Orsolya Zámbó; Éva Remenár; László Tamás; Miklós Kásler
Journal:  Cancer Imaging       Date:  2016-11-04       Impact factor: 3.909

9.  Imaging in laryngeal cancers.

Authors:  Varsha M Joshi; Vineet Wadhwa; Suresh K Mukherji
Journal:  Indian J Radiol Imaging       Date:  2012-07

10.  Maximum Standardized Uptake Value (SUVmax) of Primary Tumor Predicts Occult Neck Metastasis in Oral Cancer.

Authors:  Grégoire B Morand; Domenic G Vital; Ken Kudura; Jonas Werner; Sandro J Stoeckli; Gerhard F Huber; Martin W Huellner
Journal:  Sci Rep       Date:  2018-08-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.